(Q42723596)

5 November 2017

Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes (English)

1 reference

5 November 2017

1 reference

1 reference

Ronald Christopher

1

1 reference

5 November 2017

Aziz Karim

series ordinal

2

1 reference

5 November 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Review of Clinical Pharmacology

5 November 2017

1 reference

5 November 2017

2

1 reference

5 November 2017

6

1 reference

5 November 2017

589-600

1 reference

Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?

5 November 2017

1 reference

Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies

21 January 2018

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives

21 January 2018

1 reference

Standards of medical care in diabetes--2008.

21 January 2018

1 reference

Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus

21 January 2018

1 reference

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

21 January 2018

1 reference

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

21 January 2018

1 reference

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

21 January 2018

1 reference

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

Postmenopausal hormone therapy for disease prevention: have we learned any lessons from the past?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.09.45

1 reference

release_tekiwuieujd2njanqjgzceyrqi

5 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tekiwuieujd2njanqjgzceyrqi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference